Teva's Buy of Ratiopharm Conditional

Pharmaceutical firm Teva may go ahead with its €3.7 billion takeover of German generic drugmaker Ratiopharm if the companies divest products in the Netherlands and Hungary, the European Commission said on Wednesday.

"The decision is conditional upon the divestment of 15 products in the Netherlands and one in Hungary. The Commission had concerns that the parties' high combined market shares for these products, together with their overall post-merger strength in the Netherlands, could have harmed competition on these markets," the European Union's executive said.

The merger is to reinforce Teva's presence in the world's second-largest generics market. Teva, the world's largest generics drug manufacturer, will also gain a stronger market position in Spain, Italy and France through the deal, which it announced in March.

The combined company would have had revenues of $16.2 billion in 2009. Teva has said that cost savings from the acquisition are expected to amount to at least $400 million within three years of closing the deal.

Teva announced the Commission's decision on Tuesday, but provided no details.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.